About eight years after its Series B, a small biotech working on non-opioid treatments has raised its Series C to gather clinical proof of concept in acute...
1 month ago

The FDA is weighing the regulatory fate of Vertex's small-molecule suzetrigine, an inhibitor of voltage-gated sodium channel 1.8 (Na V 1.8), for moderate to...
1 month ago

Sugar is a silent killer and a new UC Davis study finds that overconsumption can lead to several painful gastrointestinal diseases that this new medication...
1 month ago

With Neural Ice, the company's groundbreaking drug-free therapy, Brixton aims to offer ultra-long-lasting pain relief with a simple injection.
1 month ago

Virpax Pharmaceuticals advances development of NES100, a breakthrough nasal spray using nanotechnology to deliver pain relief without opioid-related side...
1 month ago

Ijeoma Uchegbu discusses nanomedicine's role in improving medication adherence and developing non-addictive pain relief solutions at ELRIG Drug Discovery...
2 months ago

The sciatica study results, expected shortly, will be crucial for Vertex, and for people wracked by chronic pain.
2 months ago

Researchers have developed a non-addictive painkiller that remains inactive until it reaches sites of chronic pain. Instead of dulling the nerves that send...
2 months ago

Better pain medications, known as Nav1.8 inhibitors, could be the first new drugs in decades for chronic pain conditions that don't respond to existing.
2 months ago

Axonis Therapeutics, a biotech company that has been quietly operating for the last five years, has raised $115 million after retooling its drug pipeline.
2 months ago